Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Overview

Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.

Full Title of Study: “Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study of INV-102 Ophthalmic Solution in Patients With Acute Infectious Keratoconjunctivitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 2024

Interventions

  • Drug: INV-102
    • INV-102 Ophthalmic Solution
  • Drug: Vehicle
    • Vehicle Ophthalmic Solution

Arms, Groups and Cohorts

  • Experimental: INV-102 0.7% Three Times per Day (TID)
    • INV-102 ophthalmic solution administered for about 1 week
  • Placebo Comparator: Vehicle TID
    • INV-102 ophthalmic solution administered for about 1 week

Clinical Trial Outcome Measures

Primary Measures

  • To Evaluate the Change in Combined Clinical Score
    • Time Frame: Through End of Treatment (Day 8)
    • To evaluate the efficacy of INV-102 compared to vehicle control in reducing Combined Clinical Score (bulbar hyperemia plus conjunctival discharge) in patients with AIK. Conjunctival hyperemia will be rated by using the modified version of Cornea and Contact Lens Research Unit grading scale for bulbar redness, which ranges from 0 (none) to 4 points (very severe). Conjunctival discharge will be assessed using the chart below from Schwab and Friedlander (2002) to score conjunctival discharge from 0 (absent/normal) to 3 (severe).

Secondary Measures

  • To Evaluate the Percent of participants requiring rescue
    • Time Frame: Day 3
    • To evaluate the percent of patients requiring rescue therapy from Day 3 in the INV-102 arm compared to vehicle control

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female patient ≥ 18 years of age – A clinical diagnosis of AIK with a minimum of a 2+ (moderate) conjunctival hyperemia and a minimum of 1+ (mild) discharge (whether it be watery or purulent) in at least one eye Exclusion Criteria:

  • Untreated keratoconjunctivitis of any type that has lasted 96 consecutive hours or more prior to baseline visit – Infectious blepharitis as the primary cause of ocular hyperemia and discharge in the opinion of the investigator (Note: If the blepharitis is secondary to the conjunctivitis, the patient can be included) – Suspected allergic conjunctivitis as a primary cause of conjunctival hyperemia (bulbar redness) and/or discharge in the opinion of the Investigator – Suspected corneal ulcer – Ocular topical steroid use within two weeks prior to baseline visit – Ocular topical antibiotic use for less than 24 hours or greater than 96 hours of dosing prior to Baseline visit (this does NOT exclude naïve patients or patients that have not taken topical antibiotics) – Ocular topical povidone iodine use within 1 week prior to baseline visit – Systemic antibiotic use within 2 weeks prior to baseline visit – Ocular topical or systemic anti-fungal within 2 weeks prior to baseline visit – Ocular topical or systemic anti-viral use within 2 weeks prior to baseline visit – Corticosteroid (including but not limited to oral, intranasal, inhaled, topical, etc.) or any immunosuppressant use within 30 days prior to Baseline visit – On current treatment for herpes keratitis (evidence of herpes keratitis and/or ocular dendrites can be included) – Known or suspected ocular fungal infection or ocular microsporidia infection

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Invirsa, Inc.
  • Collaborator
    • Biomedical Advanced Research and Development Authority
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Invirsa Call Center, +1 614-334-1765, info@invirsa.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.